<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131057">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01817777</url>
  </required_header>
  <id_info>
    <org_study_id>116086</org_study_id>
    <nct_id>NCT01817777</nct_id>
  </id_info>
  <brief_title>An Open Study to Evaluate Whether Pack Size Affects Compliance of Metformin Treatment in Subjects With Type II Diabetes</brief_title>
  <official_title>A Pharmacy Based Open Study to Evaluate Whether Pack Size Affects Compliance for Subjects Diagnosed With Diabetes Type II Who Are Established on Metformin Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MTF116086 is an open-label, randomised, parallel-design study in subjects with type II
      diabetes. The study is site-based, with local pharmacies serving as the sites and
      pharmacists as principal investigators for the sites. All subjects will enter an initial
      8-week observational phase during which purchase behaviour and compliance with usual
      metformin use will be observed and recorded. At the end of the observational phase, subjects
      will be randomised to one of the two arms (metformin small pack vs. metformin large pack)
      for a 20-week interventional phase. The medication in the interventional phase is provided
      to the subjects free of charge. HbA1c will be collected for all subjects during Week 0, Week
      8, and Week 28. Subjects will be asked questions about their tablet compliance, their
      satisfaction with the pack size they received and reasons for missing doses throughout the
      interventional phase by the pharmacist. The pharmacy visit on Week 28 will be end of the
      study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    It's no longer feasible to continue to recruit patients into the study as severe recruitment
    difficulties have been experienced since the study start
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in haemoglobin A1c (HbA1c)</measure>
    <time_frame>Week 8 and Week 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>HbA1c will be assessed for all subjects at three time points: enrolment (Week 0), baseline (Week 8), and end of study (Week 28). During the corresponding pharmacy visit for each of these time points, HbA1c will be tested with a point-of-care device, which requires a finger prick to obtain blood and provides an immediate result upon analysis in the device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent compliance throughout Interventional phase</measure>
    <time_frame>20 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compliance for the study will be estimated as a percentage, with the denominator being the number of pills dispensed by the pharmacist and the numerator the number of pills taken, accounting for any pills that the subject has remaining at subsequent pharmacy visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent compliance throughout Observational phase</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compliance will be estimated during the 8 week observational phase for usual metformin treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days zero metformin pills were taken</measure>
    <time_frame>28 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Frequency and proportion of days with no metformin dose taken by the subject will be summarised</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with diabetes disease management modifications</measure>
    <time_frame>28 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects prescribed add-on diabetes therapy during study. Throughout the duration of the study, subjects will remain on their recommended metformin dosing regimens, unless a change of metformin dose is prescribed by their physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects requiring a non-routine health care professional visit (for diabetes)</measure>
    <time_frame>28 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects visiting a health care professional for diabetes management during study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who prefer their treatment regimens during the study</measure>
    <time_frame>28 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects who preferred their treatment regimens during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for missed metformin days/doses</measure>
    <time_frame>28 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reason for missed days/dose will be summarised</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects withdrawn from study</measure>
    <time_frame>28 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>A subject may voluntarily discontinue participation in this study at any time or be withdrawn by the investigator for pre-defined reasons</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Metformin Small Pack Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin small pack arm will receive medication free of charge in a small pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin Large Pack Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin large pack arm will receive medication free of charge in a large, monthly pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Small Pack</intervention_name>
    <description>A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.</description>
    <arm_group_label>Metformin Small Pack Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Large Pack</intervention_name>
    <description>The large pack will consist of 1 month's supply of metformin.</description>
    <arm_group_label>Metformin Large Pack Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females of age &gt;=18 years

          -  Diagnosis of type II diabetes

          -  HbA1c value no higher than 9.0%

          -  Evidence of physician-supplied prescription for metformin use

          -  Stable dose of metformin for 3 months prior to enrolment

          -  Written informed consent from the subject

        Exclusion Criteria:

          -  Current use of any anti-diabetic medication other than metformin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Correintes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5539</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5515</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Provincia de Buenos Aires</city>
        <zip>1754</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucum√°n</city>
        <zip>T 4000IOE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Socioeconomic category</keyword>
  <keyword>Medication compliance</keyword>
  <keyword>Metformin</keyword>
  <keyword>small pack</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
